Early signs like wheezing, cough, and chest pain can give way to other symptoms, such as joint pain or facial swelling, as the cancer spreads. Like other cancers, non-small cell lung cancer can ...

Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with a high metastatic potential. Treatment with chemotherapy can produce high response rates, but potential relapse rates are ...

PSAT1 and PSRC1 are upregulated in SCLC, with PSRC1 linked to lower survival rates, suggesting potential therapeutic targets. COLEC12, PLLP, and HP are downregulated, affecting immune response and ...

Anti-amphiphysin I antibodies have also been identified in a few patients with paraneoplastic neurological disorders (PND) and small cell lung cancer (SCLC). The frequency of anti-amphiphysin I ...

“Receiving an Orphan Drug Designation for ZL-1310 recognizes its potential to treat patients with SCLC. These patients have an urgent need for innovative treatment options with improved ...

Introduction Small Cell Lung Cancer (SCLC) typically responds well to initial chemotherapy with Etoposide and a platinum-containing agent. However survival is poor due to invariable relapse with ...

Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results from the ADRIATIC trial, in which patients were treated with Imfinzi for ...